Biotech Values

[DFRAI]

TRIL - a single investor slated to take up the offering

and nominate a BOD person.

I would expect this BOD to become more active and entertain partnerships to create value. Clearly the management made an error not to capitalize on their share price last year. Even after all clinical issues present then seemed to me that were resolved in subsequent press releases - share price did not rebound = lack of trust in mgmt.